Most Americans turn to Medicare after their 65th birthdays to give them the assistance they need to cover their healthcare expenses. With estimates of total lifetime medical costs for retired couples soaring toward the $300,000 mark, you can't afford not to make the most of the Medicare benefits to which you're entitled.
Every year, Medicare gives its participants the chance to make key changes to their coverage during the annual open enrollment period. With a start date of Oct. 15, it's smart to take the time now to prepare yourself for the choices you'll have once open enrollment begins. That way, you'll be in the best position possible to use open enrollment to get more value out of your Medicare coverage. Here's some basic information about how Medicare open enrollment works, along with some tips to help you figure out the best way for you to navigate it.
Image source: Getty Images.
Top Medical Stocks To Buy For 2019: Goldman Sachs BDC, Inc.(GSBD)
Advisors' Opinion:- [By Shane Hupp]
Goldman Sachs BDC Inc (NYSE:GSBD) has been given a consensus rating of “Hold” by the eleven analysts that are presently covering the stock, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating, two have assigned a buy rating and two have assigned a strong buy rating to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $22.50.
- [By Motley Fool Transcribers]
Goldman Sachs BDC, Inc. (NYSE:GSBD)Q4 2018 Earnings Conference CallMarch 01, 2019, 9:00 a.m. ET
Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks:Operator
- [By Max Byerly]
Stifel Financial Corp trimmed its position in Goldman Sachs BDC Inc (NYSE:GSBD) by 48.5% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 12,440 shares of the financial services provider’s stock after selling 11,736 shares during the quarter. Stifel Financial Corp’s holdings in Goldman Sachs BDC were worth $238,000 at the end of the most recent reporting period.
- [By Ethan Ryder]
Goldman Sachs BDC (NYSE:GSBD) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $25.00 target price on the stock. According to Zacks, “Goldman Sachs BDC, Inc. is a specialty finance company. The Company invests primarily in telecommunication services, electronic equipment, instruments and components and real estate management and development industries. Goldman Sachs BDC, Inc. is based in NEW YORK, United States. “
Top Medical Stocks To Buy For 2019: Cidara Therapeutics, Inc.(CDTX)
Advisors' Opinion:- [By Joseph Griffin]
These are some of the news headlines that may have impacted Accern’s scoring:
Get Cidara Therapeutics alerts: Statement re Appointment of Matthew Onaitis as Chief Financial Officer (businesswire.com) Mainstay Medical Announces the Appointment of Matthew Onaitis as Chief Financial Officer (businesswire.com) Cidara finance chief bids adieu (seekingalpha.com) Cidara Therapeutics Inc (CDTX) Receives Average Recommendation of “Buy” from Brokerages (americanbankingnews.com)Shares of CDTX stock traded down $0.05 on Wednesday, hitting $4.35. 6,508 shares of the stock traded hands, compared to its average volume of 98,568. The company has a current ratio of 7.11, a quick ratio of 7.11 and a debt-to-equity ratio of 0.12. The firm has a market cap of $120.40 million, a P/E ratio of -1.37 and a beta of 1.99. Cidara Therapeutics has a 1-year low of $3.65 and a 1-year high of $8.80.
- [By Trey Thoelcke]
This small-cap biotech company also has big-time potential. Cidara Therapeutics Inc. (NASDAQ: CDTX) is a clinical-stage biotechnology company is engaged in the discovery, development and commercialization of anti-infectives. It is developing a pipeline of product and development candidates with a focus on serious fungal infections.
- [By Chris Lange]
Cidara Therapeutics Inc. (NASDAQ: CDTX) shares took a big step back on Monday, despite the firm reporting positive midstage results. Specifically, Cidara reported positive topline results from its Phase 2 Strive clinical trial of its lead antifungal candidate rezafungin acetate.
- [By Max Byerly]
Get a free copy of the Zacks research report on Cidara Therapeutics (CDTX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Top Medical Stocks To Buy For 2019: ANSYS, Inc.(ANSS)
Advisors' Opinion:- [By Ethan Ryder]
ANSYS (NASDAQ: ANSS) and Okta (NASDAQ:OKTA) are both computer and technology companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends and earnings.
- [By Ethan Ryder]
Get a free copy of the Zacks research report on Ansys (ANSS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Stephan Byrd]
Ansys (NASDAQ:ANSS) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “ANSYS delivered strong results for first-quarter 2018, wherein both the top and bottom lines fared better than the respective Zacks Consensus Estimates. Increasing demand for simulation particularly from industries like energy bodes well for ANSYS. We believe that robust product portfolio, expanding total addressable market improving enterprise penetration, collaborations with leading vendors, and strong balance sheet are the catalysts. Acquisitions like 3DSIM and OPTIS are not only enabling ANSYS to bring innovative solutions to the market but are also aiding it to enhance foothold in the competitive simulations market. However, its margin is expected to remain under pressure as ANSYS continues to invest on product development. Furthermore, adverse foreign currency exchange rates are expected to impede revenue growth in the near term as it generates significant revenues from international market.”
Top Medical Stocks To Buy For 2019: Gol Linhas Aereas Inteligentes S.A.(GOL)
Advisors' Opinion:- [By Max Byerly]
Gol Transportes Aéreos (NYSE:GOL) shares traded down 5.4% on Monday . The company traded as low as $9.72 and last traded at $9.75. 524,965 shares traded hands during mid-day trading, an increase of 40% from the average session volume of 374,811 shares. The stock had previously closed at $10.31.
- [By Logan Wallace]
Gol Linhas Aereas Inteligentes SA (NYSE:GOL) has received an average rating of “Hold” from the six analysts that are presently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $8.67.
- [By Max Byerly]
Get a free copy of the Zacks research report on Gol Linhas Aereas Inteligentes (GOL)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
No comments:
Post a Comment